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Abstract
Cancer treatment often tends to involve direct targeting enzymes essential for the growth and proliferation of cancer cells. 
The aim of this study was the recognition of the possible role of selected protein kinases: PI3K, ERK1/2, and mTOR in cell 
proliferation and cell cycle in malignant melanoma. We investigated the role of protein kinase inhibitors: U0126 (ERK1/2), 
LY294002 (PI3K), rapamycin (mTOR), everolimus (mTOR), GDC-0879 (B-RAF), and CHIR-99021 (GSK3beta) in cell 
proliferation and expression of crucial regulatory cell cycle proteins in human melanoma cells: WM793 (VGP) and Lu1205 
(metastatic). They were used either individually or in various combinations. The study on the effect of signaling kinases 
inhibitors on proliferation—BrdU ELISA test after 48–72 h. Their effect on the expression of cell cycle regulatory proteins: 
cyclin D1 and D3, cyclin-dependent kinase CDK4 and CDK6, and cell cycle inhibitors: p16, p21, and p27, was studied at 
the protein level (western blot). Treatment of melanoma cells with protein kinase inhibitors led to significantly decreased 
cell proliferation except the use of a GSK-3β kinase inhibitors—CHIR-99021. The significant decrease in the expression of 
selected cyclins and cyclin-dependent kinases (CDKs) with parallel increase in the expression of some of cyclin-dependent 
kinases inhibitors and in consequence meaningful reduction in melanoma cell proliferation by the combinations of inhibitors 
of signaling kinases clearly showed the crucial role of AKT, ERK 1/2, and mTOR signal transduction in melanoma progres-
sion. The results unanimously indicate those pathways as an important target for treatment of melanoma.
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Introduction
Treatment of melanoma causes many problems as melanoma 
is a heterogeneous disease, resistant to standard chemo-
therapy, and only subsets of patients respond to systemic 
therapies [1–3].
The transformation of melanocytes to melanoma cells 
is characterized by uncontrolled proliferation as a result 
of abnormalities in cell cycle regulatory mechanisms. In 
normal cells, the cell cycle is controlled at multiple stages 
related to DNA replication, cell division, and cell growth 
[4]. This process also includes mechanisms to ensure that 
errors are corrected, and if not, the cells commit suicide 
(apoptosis) [5].
In melanoma, genetic mutations leading to disturbance 
of these regulatory mechanisms result in uncontrolled cell 
proliferation [4, 6]. The regulation of cell proliferation is 
essential for normal development and response to patho-
logical processes such as cell damage and tumorigenesis. 
Progression through the cell cycle is controlled by cyclins, 
cyclin-dependent kinases, and inhibitory proteins. Cyclin 
D1 is usually associated with CDK4, whereas cyclin D3 
preferentially partners CDK6 [7].
Cyclins, cyclin-dependent kinases, and inhibitory pro-
teins play an important role in the regulation of cell prolif-
eration, through the G1 restriction point by regulating the 
function of pRb (retinoblastoma protein) [8].
Cancerous phenotypes result from the dysregulation 
of more than 500 genes at multiple steps in cell signaling 
pathways. Most melanomas are driven by BRAF(V600E)-
activating mutations [9].
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Potential synergy exists between the combination of 
CDK4/6 inhibitors with existing therapies targeting the 
MAPK pathway, particularly in subsets of metastatic mela-
nomas such as NRAS and BRAF mutants [3, 10].
In case of V600 BRAF mutation, it seems effective to 
use RAF inhibitors; RAS and NF1-mutant melanomas have 
deregulated MEK signaling pathways that are highly sensi-
tive to MEK kinase inhibitors [11], while overexpression 
of AKT3 isoforms that affects MEK and mTOR signaling 
pathways has been observed with: wild-type RAS NF1 and 
Triple Wild-Type cancers, suggesting effective use of target 
therapy for MEK and PI3K/AKT/mTOR signaling pathway 
[11].
Activation of mammalian target of rapamycin (mTOR) 
signaling has been demonstrated in aggressive cancers such 
as gastric [12] and cervical cancer [13]. The effect of mTOR 
signaling has also been observed in bladder cancer [14]. The 
expression of phospho-S6 (a marker of mTOR activity) was 
found in 55% of muscle-invasive bladder cancers with evi-
dent lymph node metastases [15]. mTOR activity was dem-
onstrated to be associated with increased pathological stage 
and reduced patient survival [15]. Recent research suggests 
that mTOR mutations often occur in melanoma patients and 
are of worse therapeutic prognosis [16]. Clinical trials with 
PI3K/AKT/mTOR pathway inhibitors may be beneficial for 
melanoma patients with specific mTOR mutations [16].
Understanding melanoma at the molecular level and iden-
tifying its novel molecular targets are needed to improve 
therapeutic strategies. Therefore, the purpose of this study 
was to recognize the effect of selected signaling kinase 
inhibitors on melanoma cells proliferation and the expres-
sion of cell cycle regulatory proteins.
Materials and methods
Cell culture
Human melanoma cell lines: WM793 [vertical-growth phase 
(VGP)]—Lu1205 (metastatic; biopsy taken from the lung; 
selection in mice; a culture from the primary site (sternum 
area) from the same donor as WM793). Cells were cul-
tured in RPMI 1640 medium supplemented with 10% fetal 
bovine serum and antibiotics: penicillin and streptomycin. 
Cells were incubated at 37 °C in a humidified atmosphere of 
5%  CO2 in air. Cells were treated with inhibitors: (1) PI3K-
LY294002 (Cell Signaling TM)—20 μM concentration, (2) 
ERK1/2-U0126 (Cell Signaling TM)—10 μM concentra-
tion, (3) mTOR—rapamycin (Selleck)—5 nM concentration, 
(4) mTOR—everolimus (Selleck)—5 nM concentration, 
(5) B-RAF-GDC-0879 (Selleck)—2 μM concentration, (6) 
GSK-3β-CHIR-99021(Selleck)—2 μM concentration. Cells 
were obtained from the ESTDAB Melanoma Cell Bank 
(Tubingen, Germany).
Cell proliferation assay
The proliferation of cells was assessed with the BrdU ELISA 
test (Roche) after 48–72 h, as described previously [17].
Cytotoxicity assay
Cytotoxicity of PI3K inhibitor—LY294002 (20  μM), 
ERK1/2 inhibitor—U0126 (10 μM), mTOR inhibitor—rapa-
mycin and everolimus (5 nM), B-RAF-GDC-0879 (2 μM) 
and GSK-3β-CHIR-99021 (2 μM) assay was determined 
using Cytotoxicity Detection Kit LDH, Roche, Germany. 
In all examined melanoma cell lines, inhibitors LY294002, 
U0126, rapamycin, everolimus, GDC-0879, and CHIR-
99021 showed no cytotoxicity effect tested in a culture 
medium at the time of 72 h. LDH activity in the culture 
medium in no case exceeded 3%.
Western blot analysis
Preparation of samples for electrophoresis and western blot 
analysis as described previously [17]. They used to analyze 
the following antibodies: Cyclin D1 (#2926 Cell Signaling 
TM), cyclin D3 (#2936 Cell Signaling TM), CDK4 kinase 
(#2906 Cell Signaling TM), CDK6 kinase (#3136 Cell Sign-
aling TM), p16 (#4824 Cell Signaling TM), p21(#2946 Cell 
Signaling TM), p27 (#2552 Cell Signaling TM), and β-actin 
(A2228, SIGMA).
Densitometry analysis
Densitometry analyses of western blot analysis were per-
formed on raw volume (sum of intensities of bound—vol-
ume calculated from the area of the peak) using SynGene 
Gene Tools version 4.03.0 (Synoptics Ltd Beacon House, 
Nuffield Road Cambridge, CB4 1TF, UK).
Statistics
Cell proliferation data were calculated from mean eight val-
ues of three times replicate experiments. All results are pre-
sented as experimental mean values which were compared 
using one-way ANOVA with the Tukey’s post hoc test (Sta-
tistica ver. 12, StatSoft); asterisk (*) indicates a significant 
difference: *p < 0.05, **p < 0.005, ***p < 0.0005.
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Results
Cell proliferation
The study of the role of protein kinases inhibitors on 
proliferation of melanoma cells was performed using the 
BrdU ELISA test after 48–72 h. We did not observe cyto-
toxic effect of none of the tested protein kinase inhibi-
tors. In the case of each of them used in indicated con-
centrations: (1) PI3K inhibitor—LY294002 (20 μM), (2) 
ERK1/2 inhibitor—U0126 (10 μM), (3) mTOR inhibi-
tors—rapamycin and everolimus (both 5 nM), (4) B-RAF 
inhibitor—GDC-0879 (2 μM), and (5) GSK-3β inhibitor—
CHIR-99021 (2 μM) either alone or in various combina-
tions the LDH activity in the media of cells treated for 
72 h did not exceed 3%.
Metastatic melanoma cell line—Lu1205, showed larger 
decreases in cell proliferation than the primary one, WM793. 
The treatment of Lu1205 cells with individual inhibitors 
of mTOR either everolimus (p < 0.0005) or rapamycin 
(p < 0.0005) and PI3K inhibitor LY294002 (p < 0.0005) 
Fig. 1  Effect of protein kinase inhibitors on melanoma cell prolif-
eration (a). The effect of combination of protein kinase inhibitors 
on melanoma cells proliferation (b). The proliferation of cells was 
assessed with the BrdU ELISA test after 48 h and 72 h. Values are 
expressed as mean ± standard deviation in 8 wells in three independ-
ent experiments. All results are presented as experimental mean val-
ues which were compared using one-way ANOVA with the Tukey’s 
post hoc test (Statistica ver. 12, StatSoft); asterisk (*) indicates a sig-
nificant difference: *p < 0.05, **p < 0.005, ***p < 0.0005
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for 48 h led to the reduction in their proliferation in the 
range of 12–34% (Fig. 1a). The use of n GSK-3β kinase 
inhibitors—CHIR-99021, did not cause any decrease in cell 
proliferation.
The prolongation of treatment of Lu1205 metastatic 
melanoma cells up to 72 h led in the case of all the used 
inhibitors to significant reduction in their proliferation, 
reaching about 50%, for each of the three of them already 
mentioned above—everolimus (p < 0.0005), rapamycin 
(p < 0.0005), and LY294002 (p < 0.005). The treatment 
of Lu1205 cells with U0126 (ERK1/2 inhibitor) reduced 
proliferation about 34% (p < 0.0005), whereas their treat-
ment with B-RAF inhibitor—GDC-0879, only to about 24% 
(p < 0.005) (Fig. 1a).
The use of the combination of inhibitors U126 (ERK1/2) 
and GDC-0879 (B-RAF), each with the mTOR inhibi-
tor—everolimus, resulted in more effective, nearly 60% 
(p  <  0.0005) reduction in Lu1205 cells proliferation 
(Fig.  1b). The most profound inhibition was, however, 
noticed in the case of applications of the combination of 
mTOR inhibitor—everolimus, with PI3K kinase inhibi-
tor—LY294002, which reduced proliferation of Lu1205 
metastatic melanoma cells by 62% (p < 0.0005) in (Fig. 1b).
WM793 cells from primary site (VGP) did not respond as 
effectively as the metastatic ones (Lu1205) to the treatment 
with each of the inhibitors used in the individual mode since 
48-h incubation had almost no effect on their proliferation, 
while the prolongation of the incubation up to 72 h led to its 
25–30% reduction in the case of everolimus (p < 0.0005), 
rapamycin (p < 0.05), and LY294002 (p < 0.0005) (Fig. 1a).
The use of the various combinations of the studied inhibi-
tors resulted in higher reduction in WM793 cells prolifera-
tion, however, not as high as in the case of Lu1205 cells 
(Fig. 1b). Again in the case of everolimus and LY294002 
(p < 0.0005) as well as U126 and LY294002 (p < 0.0005) 
used together, the decrease in the proliferation was the high-
est one, reaching nearly 36% (Fig. 1b).
Effect of protein kinases inhibitors on cell cycle 
regulatory proteins in melanoma cells
We also studied the effect of using the individual inhibi-
tors: PI3K inhibitor—LY294002, ERK1/2-U0126; mTOR: 
rapamycin and everolimus; B-RAF-GDC-0879 and GSK-
3β-CHIR-99021; and their combination on the expression 
of cell cycle regulatory proteins: cyclin D1 and D3, cyclin-
dependent kinase: CDK4, CDK6, and cell cycle inhibitors: 
p16, p21, and p27.
In both studied melanoma cell lines expression of cyc-
lins D1 and D3, cyclin-dependent kinases CDK4 and CDK6 
were observed (Fig. 2a, b). The level of the expression of 
cyclin D3 in untreated cells was much higher than the level 
of cyclin D1, and it was much higher for both cyclins: D1 
and D3 in the case of metastatic Lu 1205 cells than in 
WM793 primary ones.
The level of cyclin D3 and cyclin-dependent kinase 6 
(CDK6) was most decreased after the application of mTOR 
inhibitors: rapamycin or everolimus (~ 60–75% relative 
to the untreated cells). Similar results were obtained after 
application of inhibitor LY294002 (~ 60–70% reduction). 
CHIR-99021-GSK-3β inhibitor did not affect the level of 
kinase CDK6 and cyclin D3 (Fig. 2a, b).
In the case of the use of single protein kinase inhibitors, 
largest decreases in cyclin D1 and cyclin-dependent kinase 
4 (CDK4) expression were observed for ERK1/2-U126 and 
B-RAF-GDC-0879—about 50–70% relative to the control; a 
little smaller effect was observed for PI3K kinase inhibitor—
LY294002—about 50%, and for the inhibitor of GSK-3β 
kinase—CHIR-99021, the effect was not observed (Fig. 2a, 
b).
The expression of the cell cycle inhibitors p16, p21, and 
p27 in untreated (control) cells was initially low in both 
studied melanoma cell lines. Their level increased upon 
application of each of the tested protein kinases inhibitors, 
yet the greatest increase was observed following the use of 
mTOR inhibitors: rapamycin and everolimus—about 70%, 
and B-RAF inhibitor GDC-0879—about 60% (Fig. 2a, b).
The greatest simultaneous decline of cyclin D1, CDK4 
kinase, and cyclin D3 and CDK6 kinase was observed after 
treatment of melanoma cell with the combination of inhibi-
tors: mTOR—everolimus, with ERK1/2 inhibitor—U126 or 
B-RAF-GDC-0879 (Fig. 3a, b). The use of the combina-
tion of inhibitors everolimus and LY294002 gave notice-
able effects on decrease in the level of cyclin D3 and CDK6 
kinase by 60–80%, while the use of the combination of 
inhibitors U126 and LY294002 caused a similar decline in 
cyclin D1 and CDK4 kinase (Fig. 3a, b).
The decline in the level of cyclins D1 and D3, and cyclin-
dependent kinases (CDK4, CDK6) was accompanied by the 
increase in the level of protein: p16, p21, and p27 (Fig. 3a, 
b).
Discussion
In this study, we were able to show that all but one selected 
(tested) protein kinases inhibitors: PI3K (LY294002), 
ERK1/2 (U0126), mTOR (rapamycin and everolimus), 
B-RAF (GDC-0879), and GSK-3β (CHIR-99021) used 
individually or in combination had strong anti-proliferative 
effect on melanoma cell lines. In the case of treatment of 
melanoma cells with each of inhibitors used in individual 
mode, the best results were obtained for mTOR inhibitor 
(either everolimus or rapamycin). It is worth to notice that 
the significant reduction in proliferation was observed for as 
low as 5 nM inhibitor’s concentration which lays within the 
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range of recommended dose for treatment of human ovarian 
cancer (3–8 nM) [18].
A little less effective in that respect were PI3K and 
ERK1/2 inhibitors—LY294002 and U126, respectively.
In the case of an inhibitor of GSK-3β (CHIR-99021), 
no effect on proliferation after 48-h treatment was found. 
Similar results on the use of CHIR-99021 inhibitor were 
reported by [19]; GSK-3β inhibition promotes proliferation 
and neuronal differentiation of human-induced pluripotent 
stem cell-derived neural progenitors [20]. On the other 
hand, induction of apoptosis in pancreatic cancer cells was 
observed after application of GSK-3β (CHIR-99021) kinase 
inhibitor [21].
We therefore sought to see if inhibition of that important 
kinase might have any effect in the case of melanoma cells.
Application of the combination of protein kinase inhibi-
tors gave better results than the use of inhibitors individually. 
The best results were obtained while using a combination 
Fig. 2  Effect of protein kinase inhibitors on cell cycle protein in 
melanoma cells. Melanoma cell lines: a WM793, b Lu1205 were 
treated with protein kinase inhibitors. Cell cycle protein expression 
was analyzed by western blot. Densitometry analyses of western blot 
were performed on raw volume (sum of intensities of bound-volume 
calculated from the area of the peak) using SynGene Gene Tools ver-
sion 4.03.0 (Synoptics Ltd Beacon House, Nuffield Road Cambridge, 
CB4 1TF, UK). Densitometry was used to normalize to control (mel-
anoma cells untreated with protein kinase inhibitors). Presented are 
representative of at least three independent experiments with similar 
results
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of everolimus and LY294002. Similar results were also 
obtained for the combination of everolimus and U126 or 
GDC-0879.
The use of signaling kinases inhibitors were also shown 
to effect the expression of proteins that are involved in 
the regulation of the cell cycle which justifies their influ-
ence on melanoma cells proliferation. Treatment of mela-
noma cells with inhibitor of ERK1/2 kinase—U126 and 
B-RAF-GDC-0879, resulted in the most profound reduc-
tion in expression of cyclin D1 and CDK4 kinase but only 
slightly affected the level of cyclin D3 and CDK6 kinase. 
The use of mTOR inhibitors everolimus or rapamycin led 
to the opposite effect and resulted in a significant decrease 
in the level of cyclin D3 and CDK6 kinase while to only 
moderate decrease in cyclin D1 and CDK4 kinase levels.
Fig. 3  Effect of combination of protein kinase inhibitors on cell cycle 
protein in melanoma cells. Melanoma cell lines: a WM793, b Lu1205 
were treated with combination of protein kinase inhibitors. Cell cycle 
protein expression was analyzed by western blot. Densitometry anal-
yses of western blot were performed on raw volume (sum of inten-
sities of bound-volume calculated from the area of the peak) using 
SynGene Gene Tools version 4.03.0 (Synoptics Ltd Beacon House, 
Nuffield Road Cambridge, CB4 1TF, UK). Densitometry was used to 
normalize to control (melanoma cells untreated with protein kinase 
inhibitors). Presented are representative of at least three independent 
experiments with similar results
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Those observations remain in concert with recently 
reported results of preclinical studies carried out by a num-
ber of centers with the use of ERK1/2 inhibitors which con-
firm that the decrease in the forms of phosphorylated ERK-
pERK is accompanied by the decrease in the expression of 
cyclin D1 [22, 23]. The role of cyclin D1 in melanoma cells 
is, however, controversial. In many studies, expression of 
cyclin D1 is enhanced in primary and metastatic melanoma 
[7, 24]. On contrary, some histopathological data do not 
show a statistically significant difference in the level of this 
cyclin [25], and others suggest that cyclin D1 expression sig-
nificantly increases due to tumor progression yet decreases 
in metastases [26]. Some authors suggest that expression 
of cyclin D1 is the effect of upregulation by constitutive 
B-RAF-MEK-ERK1/2 signaling initiated by mutant B-RAF 
[7, 26, 27]. Such relation between hyperactive signaling 
pathway and cyclin D1 expression may explain its relatively 
low sensitivity to PI3K and mTOR inhibitors treatment.
According to the literature, the level of cyclin D3 is sig-
nificantly higher in melanoma than in dysplastic nevi. It 
can therefore be used as a diagnostic marker for differen-
tiation of these lesions in histologically doubtful cases [8]. 
Flørenes et al. [28] have shown that expression of cyclin 
D3 is an important factor in predicting the clinical outcome 
for patients with superficial spreading melanoma, whereas 
the level of cyclin D1 expression has no impact on tumor 
progression. The expression of cyclin D3 in melanoma cells 
is associated with regulation of the cell cycle at the G1-S 
phase, which is necessary for efficient entry into S phase, 
increased cell proliferation, and is a poor prognostic factor 
[7, 8, 28]. The data obtained by Spofford et al. [7] suggest 
that the activity of cyclin D3 is regulated by fibronectin-
mediated PI3K signaling but not ERK1/2 one, which may 
explain relatively small decrease in the level of cyclin D3 
after the application of U126.
The use of protein kinase inhibitors decreased the level 
of cyclin D1 and D3 and the cyclin-dependent kinase CDK4 
and CDK6, which was accompanied by increased expression 
of cell cycle inhibitors p16, p21, and p27.
The highest increase in p16 suppressor protein was 
observed using U126-ERK1/2 inhibitor and rapa-
mycin or everolimus—mTOR inhibitors, a significant 
increase was also observed after application B-RAF 
inhibitor—GDC-0879.
Monahan et al. [29] observed potent cooperation between 
the loss of somatic p16 and acceleration of melanoma gen-
esis, a finding consistent with the view of more prominent 
tumor suppressor role of p16 relative to p53 in human mela-
noma. Loss of p16-Rb and ARF-p53 tumor suppressor path-
ways, as well as activation of RAS–RAF signaling, is seen 
in a majority of human melanomas [29].
Use of the combination of inhibitors of signaling 
kinases led to a greater decrease in the level of cyclin 
D1 and D3 and the cyclin-dependent kinase CDK4 and 
CDK6 than the application of inhibitors in single mode. 
The largest decreases in the level of both cyclin D1 and 
D3 and proteins CDK4 and CDK6 were observed after 
treatment with the following combination of inhibitors: 
everolimus and B-RAF inhibitor GDC-0879 or everolimus 
with ERK1/2 inhibitor U126. Simultaneous application of 
inhibitor everolimus and that of PI3K-LY29004 gave lim-
ited decrease in expression of cyclin D1 and CDK4 kinase 
but significantly decreased the level of cyclin D3 and 
CDK6 kinase. However, using a combination of inhibitors 
of PI3K-LY29004 and ERK1/2-U126 resulted in decreased 
expression of cyclin D1 and CDK4 and slight decrease in 
the level of cyclin D3 and CDK6 kinase. The decline in 
the level of cyclin is accompanied by an increase in the 
level of tumor suppressor proteins p16, p21, and p27. The 
highest increase tumor suppressor protein was observed in 
combinations: mTOR inhibitor—everolimus and ERK1/2-
U126, slightly lower for the everolimus and GDC-0879.
Everolimus is a new hope for patients with breast can-
cer [30]. mTOR inhibitor everolimus (RAD001), an orally 
administered drug, was recently approved by the US-FDA 
in combination with exemestane (aromatase inhibitors) for 
treatment of “hormone receptor-positive” (HR-positive) 
metastatic breast cancer [31, 32]. Study conducted by 
a group of Lui et al. [33] demonstrated that everolimus 
inhibits the proliferation of aromatase inhibitor-resistant 
breast cancer cells through the downregulation of estro-
gen receptor expression. Another study [15] showed that 
everolimus exerts anticancer activity in bladder cancer 
cells and proposes its role in effective disturbing the 
growth of bladder cancer cells and T cell lymphoma [34]. 
Research carried out of animal models have demonstrated 
that agents targeting mTOR pathway can lead to signifi-
cant inhibition of proliferation, differentiation, and tumor 
progression in specific pancreatic ductal adenocarcinoma 
subpopulations [35].
The presented study is up to our knowledge the only 
such extensive an promising attempt to recognize and 
determine which inhibitors of most important signaling 
kinases as well as their combinations could be in future 
effectively used in treatment of various subtypes of cuta-
neous melanoma.
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